NCT02199496: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02199496 |
|---|---|
| Title | An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 19, 2015 |
| Completion date | Aug. 16, 2019 |
| Required reporting date | Aug. 15, 2020, midnight |
| Actual reporting date | Aug. 10, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |